TORONTO, Oct. 16, 2015 /PRNewswire/ -- Bionik Laboratories Corp. (OTCQX: BNKL), a pioneering medical device and robotics company with a focus in developing technologies and solutions for individuals with neurological disorders ("Bionik" or the "Company"), announced today that it was awarded a Nasdaq Entrepreneurial Center resource prize at the seventh annual Kairos Global Summit.
The award was presented to Bionik's co-founders, Thiago Caires and Michal Prywata, during the Kairos Society VIP summit event for the next generation of entrepreneurs developing breakthrough innovations, leading VCs and industry thought-leaders.
"Being recognized by the Nasdaq Entrepreneurial Center and included with such a prestigious group of K50 entrepreneurs dedicated to addressing some of the world's most difficult problems is truly an honor," commented Mr. Caires, Chief Technology Officer of the Company.
"Bionik's mission is to develop solutions for individuals with neurological disorders. We believe our ARKE™ lower-body exoskeleton has the potential to be transformational for paraplegics and other wheelchair users by significantly improving rehabilitation. We are thrilled that our advancements with ARKE were recognized this week and are committed to developing additional solutions to address significant unmet needs for people with mobility challenges," added Mr. Prywata, Bionik's Chief Operating Officer.
Following the award presentation, Bionik was featured on the Nasdaq Tower in Times Square, New York.
The resource prize provides companies access to quality education and mentorship through the newly launched Nasdaq Entrepreneurial Center in downtown San Francisco. The award includes access to one week in the center's concept store, a street-level retail space for presenting products, interacting with customers, and performing A/B testing.
About the Nasdaq Entreprenurial Center
The Nasdaq Entrepreneurial Center is a San Francisco-based non-profit organization designed to educate, innovate, and connect aspiring and current entrepreneurs. Established in 2014 with support from the Nasdaq Educational Foundation, the Nasdaq Entrepreneurial Center serves the greater Bay Area community through differentiated events, meaningful entrepreneurial education, and a strong commitment to mentorship. For more information, please visit www.thecenter.nasdaq.org.
About Bionik Laboratories
Bionik Laboratories (OTCQX: BNKL) is a pioneering medical device and robotics company with a focus in developing technologies and solutions for individuals with neurological disorders. The Bionik team has researched, developed and tested its primary product, The ARKE™, a robotic lower-body exoskeleton device that allows paraplegics and as well as other wheelchair users the ability to rehabilitate through walking and other motion. Bionik recently successfully raised approximately US$13.1 million which enables the company to rapidly advance a robust product development and growth strategy. For more information, please visit www.bioniklabs.com and connect with the Company on Twitter, LinkedIn, Facebook, and Google+.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including, the Company's current reports on Form 8-K. The Company does not undertake to update these forward-looking statements.
SOURCE Bionik Laboratories Corp.